Amyloid Beta

In addition to our program targeting the oligomerization of alpha-synuclein for treating Parkinson’s disease we have a similar program aimed at developing compounds which prevent the formation of toxic aggregates of amyloid-beta. Misfolding and aggregation of this protein plays a key role in the pathology of Alzheimer’s disease. Our efforts to target amyloid beta have resulted in the discovery of a series of compounds that prevent the aggregation of amyloid-beta in cell based assays. Initial studies in animal models suggest that these (NPT400 series) compounds have beneficial actions on neuropathology in the appropriate transgenic animal models.